glp-1 injection pen FDA Approves First Generic Liraglutide for Weight Loss GLP-1 injection pens, illustration -

However, due to its short circulating half-life, native GLP-1 is ill-suited for chronic therapy [14]

doi: 10.2174/157339508784325046 40 AschenSZampellJCElhadadSWeitmanEAndrade Brot DeMMehraraBJ

Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials The GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials one in obesity and the other Sign up to read this article for free

No FDA-approved drug products contain berberine

A life-threatening situation that should not be taken lightly

GLP-1 medications can help manage type 2 diabetes and obesity, but they may cause short-term mild-to-moderate side effects such as nausea, vomiting, diarrhoea, constipation, bloating, and decreased appetite, particularly at the beginning of treatment